MindWalk appoints Thomas Lynch as chief business officer

AUSTIN - MindWalk Holdings Corp. (NASDAQ:HYFT), a biotech AI company with a market capitalization of $83 million and annual revenue of $18.2 million, announced on Wednesday the appointment of Thomas W. Lynch, Ph.D. as Chief Business Officer, effective October 20, 2025.

Lynch brings over two decades of experience at the intersection of biotechnology and software innovation. He previously served as Director of Technical Sales & Scientific Support at Aldevron, where he built and led a global commercial team. During his tenure as Vice President of Global Sales and Client Services at Aldevron, Lynch introduced clinical mRNA manufacturing services and expanded strategic accounts, contributing to the company’s $9.6 billion acquisition by Danaher Life Sciences in 2021.

Earlier in his career, Lynch led global commercial operations at DNASTAR, where he oversaw sales, distribution, and technical support while launching protein structure prediction software products. He currently serves on the Board of BioForward, Wisconsin’s biohealth association.

"MindWalk sits at the frontier of AI-native data intelligence in life sciences," Lynch said in the press release.

MindWalk, which describes itself as a Bio-Native AI company, develops technology for drug discovery and development. The company’s platform utilizes its HYFT technology and LensAI platform to support processes such as epitope mapping, molecular design, and biologics analytics. According to InvestingPro data, the company maintains a healthy gross profit margin of 55.8% and strong liquidity with a current ratio of 2.17, though it’s currently operating at a loss.

"As we expand the reach of our HYFT-powered Deep Data platform across pharma and biotech markets worldwide, Tom’s leadership in scaling global teams and forging strategic partnerships will be instrumental," said Dr. Jennifer Bath, CEO of MindWalk, according to the company statement. The company’s stock has shown remarkable performance, delivering a 216% return over the past year. For deeper insights into HYFT’s financial health and growth potential, investors can access comprehensive analysis through InvestingPro, which offers detailed reports and additional ProTips for informed decision-making.

The appointment is part of MindWalk’s commercial strategy to increase adoption of its AI platform in the life sciences data analytics market. Based on InvestingPro’s Fair Value analysis, the stock is currently trading at fair value, with analysts expecting continued growth in the biotech AI sector.

In other recent news, MindWalk Holdings Corp. announced a share repurchase program, authorizing the buyback of up to 2.3 million common shares, which represents about 5% of its outstanding shares. This initiative will begin on October 15, 2025, and conclude by October 15, 2026. Additionally, MindWalk has expanded its GLP-1 therapeutics program by discovering a new longevity pathway using its LensAI platform, introducing a novel dual-pathway approach for potential therapeutic development. The company also completed a rebranding from ImmunoPrecise Antibodies Ltd. to MindWalk, changing its Nasdaq ticker to HYFT to reflect its focus on bio-native AI.

In another development, MindWalk has advanced its dengue vaccine program to the manufacturing phase, aiming to produce a universal vaccine candidate. The company will conduct immunization studies in Canada to assess the vaccine’s effectiveness in generating monoclonal antibody responses. Furthermore, MindWalk sold its Netherlands-based subsidiary to AVS Bio for $12 million, yielding $11.7 million in net proceeds. These recent activities highlight MindWalk’s strategic moves in advancing its AI and therapeutic programs while optimizing its corporate structure.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.